BBlogFlow

Public health intelligence - 2026 - WHO | Regional Office for Africa

·Oct 7, 2026
Source: WHO | Regional Office for Africa
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email
Photo credit : Public Health Intelligence - 2026

The WHO African Region continued to face a complex and evolving landscape of public healththreats in 2025, characterized by recurrent infectious disease outbreaks, humanitarianemergencies, climate-related disasters, and increasing cross-border health risks. PublicHealth Intelligence (PHI) remained central to WHO AFRO’s efforts to strengthen earlydetection, risk assessment, situational awareness, and evidence-based decision-makingfor health emergencies across the Region. During 2025, the Regional Public Health Intelligence team coordinated event-basedsurveillance, epidemic intelligence, rapid risk assessments, humanitarian situationanalyses, and analytical information products to support Member States and partners inresponding to acute public health events. The year also marked significant expansion ofthe Epidemic Intelligence from Open Sources (EIOS) initiative and continued integrationof innovative intelligence approaches, including speech-to-text radio mining and machinelearning-supported signal classification.

This article is an excerpt. To read the full content, visit the original source. WHO | Regional Office for Africa

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Medical Xpress·

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·